ArticleFrontiers in immunology2022

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.

Veronica Donato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.